GAITHERSBURG, Md., March 17, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company" or "Cytomedix"), a leading developer of biologically active regenerative therapies for wound care and tissue repair, today announced that it has received the Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application for the newly-designed AutoloGel™ Separation System. The original provisional patent application was filed as a result of a product development collaboration between Cytomedix and biomechanical engineers in Israel intended to fundamentally redesign the AutoloGel System. The redesign includes proprietary elements that enable a safer and significantly more rapid point-of-care procedure for the physical separation of platelets and plasma from whole blood.
